Elucidating the role of clofazimine for the treatment of tuberculosis

被引：24
作者：
O'Donnell, M. R. [1 ,2 ,3 ]
Padayatchi, N. [3 ]
Metcalfe, J. Z. [4 ]
机构：
[1] Columbia Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, 8th Floor,Suite E101,Presbyterian Hosp Bldg, New York, NY 10032 USA
[2] Columbia Univ, Med Ctr, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA
[3] CAPRISA MRC HIV TB Pathogenesis & Treatment Res U, Durban, South Africa
[4] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA
来源：
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | 2016年 / 20卷 / 12期
关键词：
TB; CFZ; treatment; MULTIDRUG-RESISTANT TUBERCULOSIS; COMMUNITY-BASED THERAPY; MYCOBACTERIUM-TUBERCULOSIS; ANTITUBERCULOSIS ACTIVITY; PULMONARY TUBERCULOSIS; STANDARDIZED TREATMENT; TREATMENT REGIMEN; RIMINO-COMPOUNDS; MOUSE MODEL; MDR-TB;
D O I：
10.5588/ijtld.16.0073
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Clofazimine (CFZ), a riminophenazine and a key component of the treatment regimen for lepromatous leprosy, has been rehabilitated clinically for the treatment of multidrug-resistant tuberculosis (MDR-TB). Observational studies and a randomized control trial suggest efficacy in the treatment of MDR-TB and the potential for treatment shortening. Animal and translational research have shown mixed results. In this article, we review key clinical, animal, and translational data to better understand the potential role of CFZ in the treatment of MDR-TB and in shortening anti-tuberculosis treatment.
引用
收藏
页码：S52 / S57
页数：6
相关论文
共 46 条
[1]   Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients [J].
Aung, K. J. M. ;
Van Deun, A. ;
Declercq, E. ;
Sarker, M. R. ;
Das, P. K. ;
Hossain, M. A. ;
Rieder, H. L. .
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2014, 18 (10) :1180-1187
[2]  
BARRY V C, 1960, Ir J Med Sci, V416, P345
[3]  
BARRY VC, 1958, AM REV TUBERC PULM, V78, P62
[4]   NEW SERIES OF PHENAZINES (RIMINO-COMPOUNDS) WITH HIGH ANTITUBERCULOSIS ACTIVITY [J].
BARRY, VC ;
BELTON, JG ;
CONALTY, ML ;
DENNENY, JM ;
EDWARD, DW ;
OSULLIVAN, JF ;
TWOMEY, D ;
WINDER, F .
NATURE, 1957, 179 (4568) :1013-1015
[5]   WHO Group 5 Drugs and Difficult Multidrug-Resistant Tuberculosis: a Systematic Review with Cohort Analysis and Meta-Analysis [J].
Chang, Kwok-Chiu ;
Yew, Wing-Wai ;
Tam, Cheuk-Ming ;
Leung, Chi-Chiu .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (09) :4097-4104
[6]  
CHANG Y T, 1955, Int J Lepr, V23, P167
[7]  
Condos Rany, 2008, Chest, V134, P187, DOI 10.1378/chest.07-1988
[8]   Clofazimine Modulates the Expression of Lipid Metabolism Proteins in Mycobacterium leprae-Infected Macrophages [J].
Degang, Yang ;
Akama, Takeshi ;
Hara, Takeshi ;
Tanigawa, Kazunari ;
Ishido, Yuko ;
Gidoh, Masaichi ;
Makino, Masahiko ;
Ishii, Norihisa ;
Suzuki, Koichi .
PLOS NEGLECTED TROPICAL DISEASES, 2012, 6 (12)
[9]   Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis [J].
Dey, Teesta ;
Brigden, Grania ;
Cox, Helen ;
Shubber, Zara ;
Cooke, Graham ;
Ford, Nathan .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (02) :284-293
[10]   Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline [J].
Diacon, Andreas H. ;
Dawson, Rodney ;
von Groote-Bidlingmaier, Florian ;
Symons, Gregory ;
Venter, Amour ;
Donald, Peter R. ;
van Niekerk, Christo ;
Everitt, Daniel ;
Hutchings, Jane ;
Burger, Divan A. ;
Schall, Robert ;
Mendel, Carl M. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191 (08) :943-953
12345